CN114127288A - 晚期糖基化终产物受体rna的调节剂和调节 - Google Patents

晚期糖基化终产物受体rna的调节剂和调节 Download PDF

Info

Publication number
CN114127288A
CN114127288A CN202080044288.6A CN202080044288A CN114127288A CN 114127288 A CN114127288 A CN 114127288A CN 202080044288 A CN202080044288 A CN 202080044288A CN 114127288 A CN114127288 A CN 114127288A
Authority
CN
China
Prior art keywords
rage
aon
aons
exon
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080044288.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·威尔顿
M·C·托马斯
C·罗萨多
R·J·皮克林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Murdoch University
Monash University
Original Assignee
Murdoch University
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901641A external-priority patent/AU2019901641A0/en
Application filed by Murdoch University, Monash University filed Critical Murdoch University
Publication of CN114127288A publication Critical patent/CN114127288A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080044288.6A 2019-05-14 2020-05-07 晚期糖基化终产物受体rna的调节剂和调节 Pending CN114127288A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2019901641A AU2019901641A0 (en) 2019-05-14 Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA
AU2019901641 2019-05-14
AU2019902095 2019-06-17
AU2019902095A AU2019902095A0 (en) 2019-06-17 Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA
AU2019902772 2019-08-02
AU2019902772A AU2019902772A0 (en) 2019-08-02 Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA
AU2019903900 2019-10-16
AU2019903900A AU2019903900A0 (en) 2019-10-16 Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA
PCT/AU2020/050449 WO2020227758A1 (en) 2019-05-14 2020-05-07 Modulators and modulation of the receptor for advanced glycation end-products rna

Publications (1)

Publication Number Publication Date
CN114127288A true CN114127288A (zh) 2022-03-01

Family

ID=73290056

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044288.6A Pending CN114127288A (zh) 2019-05-14 2020-05-07 晚期糖基化终产物受体rna的调节剂和调节

Country Status (12)

Country Link
US (3) US11441148B2 (https=)
EP (1) EP3969590A4 (https=)
JP (2) JP2022533358A (https=)
KR (1) KR20220009971A (https=)
CN (1) CN114127288A (https=)
AU (2) AU2020276337B2 (https=)
BR (1) BR112021022714A2 (https=)
CA (1) CA3140209A1 (https=)
IL (1) IL288040A (https=)
MX (1) MX2021013858A (https=)
SG (1) SG11202112144RA (https=)
WO (1) WO2020227758A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533358A (ja) 2019-05-14 2022-07-22 モナシュ ユニバーシティ 終末糖化産物受容体ｒｎａのモジュレーター及び調節
WO2024229505A1 (en) * 2023-05-05 2024-11-14 RAGE Biotech Pty Ltd Administration of oligonucleotides
AU2023447004A1 (en) * 2023-05-05 2025-10-16 RAGE Biotech Pty Ltd Methods of monitoring splicing
KR20260027924A (ko) * 2023-05-19 2026-03-03 레이지 바이오텍 피티와이 리미티드 연기 노출의 영향 최소화 방법
KR20260027923A (ko) * 2023-05-19 2026-03-03 레이지 바이오텍 피티와이 리미티드 폐 섬유증 치료 방법
AU2024352066A1 (en) * 2023-09-27 2026-04-09 Changchun Genescience Pharmaceutical Co., Ltd. New sirna, composition comprising same, and use
WO2025076595A1 (en) * 2023-10-12 2025-04-17 RAGE Biotech Pty Ltd Rnai agents targeting rage
WO2025222258A1 (en) * 2024-04-24 2025-10-30 RAGE Biotech Pty Ltd Methods of treating or preventing obstructive pulmonary disease
WO2025236048A1 (en) * 2024-05-17 2025-11-20 RAGE Biotech Pty Ltd Methods of treating the effects of smoke

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090694A2 (en) * 2002-04-24 2003-11-06 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2006119137A1 (en) * 2005-04-29 2006-11-09 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of nucleic acid at post-transcriptional level
US20100303776A1 (en) * 2009-04-16 2010-12-02 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of multiple nucleic acids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
ATE330644T1 (de) 1995-12-18 2006-07-15 Angiotech Biomaterials Corp Vernetzten polymerisatmassen und verfahren für ihre verwendung
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
JP2002537343A (ja) 1999-02-23 2002-11-05 アイシス・ファーマシューティカルス・インコーポレーテッド 多重粒子製剤
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
JP3837494B2 (ja) * 2001-03-19 2006-10-25 国立大学法人金沢大学 可溶型ｒａｇｅタンパク質
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
JP2010233542A (ja) * 2009-03-31 2010-10-21 Kanazawa Univ Ｒａｇｅ遺伝子の２種類のスプライシングバリアントを区別して増幅可能なプライマーセット及びプローブ
US9315298B2 (en) 2011-08-25 2016-04-19 Db Equipment As Accessory bag having reinforced sidewalls and variable length
WO2019222693A1 (en) * 2018-05-17 2019-11-21 Lifesplice Pharma Llc Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use
JP2022533358A (ja) 2019-05-14 2022-07-22 モナシュ ユニバーシティ 終末糖化産物受容体ｒｎａのモジュレーター及び調節

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2003090694A2 (en) * 2002-04-24 2003-11-06 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring auto immune and chronic inflammatory diseases
WO2006119137A1 (en) * 2005-04-29 2006-11-09 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of nucleic acid at post-transcriptional level
CN101213203A (zh) * 2005-04-29 2008-07-02 教堂山北卡罗莱纳州大学 在转录后水平调节核酸表达的方法和组合物
JP2008539698A (ja) * 2005-04-29 2008-11-20 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 転写後レベルでの核酸発現調節のための方法および組成物
US20100303776A1 (en) * 2009-04-16 2010-12-02 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of multiple nucleic acids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANASTASIA Z. KALEA: ""lternative splicing of RAGE: roles in biology and disease"", 《FRONTIERS IN BIOSCIENCE》, pages 2756 - 2770 *
ANNEMIEKE AARTSMA-RUS等: ""Antisense-mediated exon skipping: A versatile toolwith therapeutic and research applications"", 《RNA SOCIETY》, pages 1609 - 1624 *
张万年等: "《现代药物设计学》", 31 May 2006, 中国医药科技出版社, pages: 270 *
韩锐等: "《新世纪癌的化学预防与药物治疗》", 31 January 2005, 人民军医出版社, pages: 187 *

Also Published As

Publication number Publication date
WO2020227758A8 (en) 2021-11-18
JP2022533358A (ja) 2022-07-22
KR20220009971A (ko) 2022-01-25
US20240141360A1 (en) 2024-05-02
US20210388363A1 (en) 2021-12-16
US11441148B2 (en) 2022-09-13
AU2025223886A1 (en) 2025-09-18
WO2020227758A1 (en) 2020-11-19
US20230015481A1 (en) 2023-01-19
EP3969590A1 (en) 2022-03-23
CA3140209A1 (en) 2020-11-19
AU2020276337B2 (en) 2025-05-29
SG11202112144RA (en) 2021-11-29
US12565656B2 (en) 2026-03-03
JP2025106369A (ja) 2025-07-15
AU2020276337A1 (en) 2021-12-02
MX2021013858A (es) 2022-03-22
US11674143B2 (en) 2023-06-13
IL288040A (en) 2022-01-01
EP3969590A4 (en) 2024-05-15
BR112021022714A2 (pt) 2022-01-18

Similar Documents

Publication Publication Date Title
US12565656B2 (en) Modulators and modulation of the receptor for advanced glycation end-products RNA
JP2023519518A (ja) 疾患の処置のためのアンチセンスオリゴマー
CA3193706A1 (en) Treatment of optic atrophy
JP2025085741A (ja) 新規の網膜色素変性処置
US11459563B2 (en) Treatment for NEAT1 associated disease
CN113383076B (zh) 用于ptp1b相关病症的反义疗法
HK40069896A (en) Modulators and modulation of the receptor for advanced glycation end-products rna
RU2820247C2 (ru) Модуляторы и модуляция рнк рецептора конечных продуктов глубокого гликирования
CN114341354A (zh) 用于癌症的反义寡核苷酸疗法
US20250368988A1 (en) Compositions and Methods for Treating FUS Associated Diseases
CA3149735C (en) Antisense oligonucleotide therapy for cancer
US20250270548A1 (en) Compositions and methods for treating tardbp associated diseases
JP2018515110A (ja) 多発性硬化症の治療
JP2024541719A (ja) シクロフィリンｄ関連疾患の処置方法
CN121866333A (zh) 用于骨质流失的反义寡聚物治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40069896

Country of ref document: HK